Apogee Therapeutics Aktie News

The chief medical officer at Apogee Therapeutics sold 18,700 shares of the biotech for about $1.46 million. This sale represented 8.09% of Dambkowski's direct holdings, reducing his direct stake, as reported, from 231,223 to 212,523 shares.

10,900 shares directly sold for a total transaction value of $817,500 on Dec. 4, 2025. The transaction represented 3.87% of CMO Carl Dambkowski's direct holdings, reducing direct ownership from 282,008 to 271,108 shares.

Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up  - Results reinforce continued development in asthma testing every 3- or 6-month dosing

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asth...

Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing